Resistance in Hepatitis C
Source: Clinical Implications of HCV Resistance: Laying the Foundation for Optimal Treatment Today and in the Future

Module

Join Stephane Chevaliez, PharmD, PhD; Paul J. Pockros, MD; and Stefan Zeuzem, MD, as they review and discuss key principles of HCV resistance with currently approved direct-acting antiviral agents, the latest resistance data on agents in development, and important considerations for potential future anti-HCV regimens. These expert faculty members also provide practical strategies for clinical challenges with the newly approved direct-acting agents through a case-based analysis.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply strategies to reduce the development/expansion of resistance to direct-acting antiviral agents when managing patients receiving treatment with approved direct-acting antiviral agents in combination with peginterferon/ribavirin
  • Integrate key principles regarding antiviral resistance when evaluating data on the direct-acting antiviral agents currently in development
  • Evaluate potential future strategies for HCV treatment based on resistance considerations, including the barrier to resistance and patterns of cross-resistance among classes of direct-acting antiviral agents

Topics covered include:

  • Introduction to Drug Resistance in Hepatitis C Virus
  • Key Resistance Principles for Currently Approved Direct-Acting Antiviral Agents
  • Considerations for Retreatment of Previous Peginterferon/Ribavirin Null Responders and Potential Consequences of Protease Inhibitor Resistance
  • Genotype and Resistance Testing
  • Case 1: Previous Null Responder
  • Case 2: Stopping Rules
  • Case 3: Boceprevir Resistance–Associated Variant
  • Future Regimens
  • Future Protease Inhibitors
  • Nucleos(t)ide Polymerase Inhibitors
  • Nonnucleos(t)ide Polymerase Inhibitors
  • NS5A Inhibitors
  • Cyclophilin Inhibitors
  • Summary: Important Considerations to Avoid Resistance-Associated Variants
  • Appendix: Principles of HCV Resistance
 

Program Directors

  • Stefan Zeuzem
    MD

Faculty

  • Stéphane Chevaliez
    PharmD, PhD
    Paul J. Pockros
    MD

Credit Information

  • Release Date:
    October 25, 2011
  • Expiration Date:
    October 24, 2012
  • Physicians:
    maximum of 1.25 AMA PRA Category 1 Credits
  • Genotype 1 HCV–Infected Cirrhotic Patients: Still Hard to Treat?

    Mark S. Sulkowski MD - 6/27/2014    4 comments / Last Comment: 7/29/2014
    After a long wait, the great majority of cirrhotic patients now has a realistic chance of achieving HCV cure.
  • Are New HCV Therapies Ready for Use in Transplant Patients?

    Paul Y. Kwo MD - 7/10/2014    2 comments / Last Comment: 7/25/2014
    Paul Y. Kwo, MD, introduces some of the topics that will be discussed in an upcoming symposium in San Francisco.
  • Post-EASL Update: Reconsidering Whether to Treat Genotype 1 HCV Patients or Wait for All-Oral Therapy

    Paul Y. Kwo MD - 5/12/2014    2 comments / Last Comment: 7/23/2014
    Following the presentation of phase III data on new all-oral regimens for genotype 1 HCV at EASL, which patients might wait for the approval of new therapies and which should be treated now?
  • Post-EASL Update: How I Manage HCV Patients for Whom First-Generation Protease Inhibitors Failed

    Stefan Zeuzem MD - 5/19/2014    2 comments / Last Comment: 5/26/2014
    Following new data from the ION-2 study reported at EASL 2014, options for retreatment of patients with previous PI failure appear much improved.
  • Post-EASL Update: What Is the Role of Treatment Guidelines in the Current HCV Era?

    Jordan J. Feld MD, MPH - 5/22/2014    4 comments / Last Comment: 7/4/2014
    With the new era of HCV therapies comes a new era in clinical guidelines; although there is certainly overlap, the major guidelines serve different but important roles.